Evidence map›Paper›PMID 42023360›Full record

ReviewJournal of family medicine and primary care2026

Prescription pattern assessment of pharmacotherapeutics used in the management of amyloidosis secondary to rheumatoid arthritis via systematic review and network meta-analysis.

Aayush Sehgal, Muhammad A Shamim, Navpreet Kaur, Amol N Patil, Naveen C Hegde, Tapan Behl, Vishal Sharma, Joban Preet Singh Deol, G Naidu, Aman Sharma

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of family medicine and primary care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Aayush SehgalDepartment of Pharmacology and Toxicology, G.H.G Khalsa College of Pharmacy, Gurusar Sadhar, Ludhiana, Punjab, India.
Muhammad A ShamimDepartment of Pharmacology, All India Institute of Medical Sciences (AIIMS), Jodhpur, Rajasthan, India.
Navpreet KaurDepartment of Pharmacology and Toxicology, G.H.G Khalsa College of Pharmacy, Gurusar Sadhar, Ludhiana, Punjab, India.
Amol N PatilDepartment of Pharmacology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
Naveen C HegdeDepartment of Pharmacology, All India Institute of Medical Sciences (AIIMS), Bhubaneswar, Odisha, India.
Tapan BehlAmity School of Pharmaceutical Sciences, Amity University, Punjab, India.
Vishal SharmaDepartment of Gastroenterology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
Joban Preet Singh DeolDepartment of Internal Medicine, Division of Rheumatology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
G NaiduDepartment of Internal Medicine, Division of Rheumatology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
Aman SharmaDepartment of Internal Medicine, Division of Rheumatology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The study was conducted to determine the global prescribing behavior for amyloidosis secondary to rheumatoid arthritis (RA) and to determine the drug-specific treatment response. We checked comprehensive databases like Embase, Scopus, PubMed, and Web of Science to assess the research papers thoroughly. Studies happened from January 2001 to June 2025, were considered. Observational cohort studies reporting RA amyloidosis treatment were considered to assess naturalistic prescription patterns. Research paper quality was checked for risk of bias using a validated tool. Meta-analysis was performed with R. The study's primary outcome was to assess prescription pattern in a naturalistic, non-controlled manner. Secondary outcome was to assess the effect of different treatment agents on c-reactive protein (CRP), serum creatinine, and proteinuria in a pre-and post-treatment fashion. Twelve observational studies were identified with confirmed diagnoses in 463 RA amyloidosis patients. Etanercept was observed as the most prescribed drug. P-score for Infliximab was highest for creatinine-reducing capacity. The odds of reducing proteinuria were maximum with rituximab (OR = -4.35; C.I. = -10.24--1.54). Safety endpoint assessment showed a lower risk of infection with Etanercept (OR = 0.14; C.I. = -0.06-0.30) and highest mortality with cyclophosphamide (OR = 0.42; C.I. = -0.30-0.55). Heterogeneity was high in present meta-analysis (I

Indexed as

AA amyloidosisdisease-modifying anti-rheumatic drugsprescription patternrheumatoid arthritis

Identifiers

PMID42023360
PMCPMC13098839

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.